21804_LDL-Cholesterol Lowering and Atherosclerotic Cardiovascular Disease Risk Reduction:

n this program, lipid experts will present, in state-of-the-art lectures and in 'realworld' interactive cases, optimal strategies and provide 'take-home' messages for reducing risk in patients with elevated LDL-C.

Internists play an important role in managing patients with elevated LDL-Cholesterol (LDL-C). An awareness of guideline recommendations for the use of statin therapy, and identification of patients who have suboptimal LDL-C levels despite statin therapy and who may be considered for the addition of non-statin LDL-C lowering therapy, are critical for effective atherosclerotic cardiovascular disease (ASCVD) risk reduction. The efficacy and safety profiles of non-statin therapies such as ezetimibe and PCSK9 inhibitors must be well-understood, and recently completed cardiovascular outcome trials interpreted. Roles of non-statin therapies for LDL-C lowering in the management of ASCVD risk, as defined in recently published and updated recommendations, must be identified in order for internists to implement best clinical practice. In this program, lipid experts will present, in state-of-the-art lectures and in “real-world” interactive cases, optimal strategies and provide “take-home” messages for reducing risk in patients with elevated LDL-C.

Login to your Account